Display options
Cite
Karlsson JOG, Andersson RG, Jynge P. Mangafodipir a Selective Cytoprotectant - with Special Reference to Oxaliplatin and Its Association to Chemotherapy-Induced Peripheral Neuropathy (CIPN). Transl Oncol. 2017;10(4):641-649doi: 10.1016/j.tranon.2017.04.012.
Karlsson, J. O. G., Andersson, R. G., & Jynge, P. (2017). Mangafodipir a Selective Cytoprotectant - with Special Reference to Oxaliplatin and Its Association to Chemotherapy-Induced Peripheral Neuropathy (CIPN). Translational oncology, 10(4), 641-649. https://doi.org/10.1016/j.tranon.2017.04.012
Karlsson, Jan Olof G, et al. "Mangafodipir a Selective Cytoprotectant - with Special Reference to Oxaliplatin and Its Association to Chemotherapy-Induced Peripheral Neuropathy (CIPN)." Translational oncology vol. 10,4 (2017): 641-649. doi: https://doi.org/10.1016/j.tranon.2017.04.012
Karlsson JOG, Andersson RG, Jynge P. Mangafodipir a Selective Cytoprotectant - with Special Reference to Oxaliplatin and Its Association to Chemotherapy-Induced Peripheral Neuropathy (CIPN). Transl Oncol. 2017 Aug;10(4):641-649. doi: 10.1016/j.tranon.2017.04.012. Epub 2017 Jun 29. PMID: 28668762; PMCID: PMC5496205.
Copy Download .nbib Format: NLM
Share it on

Transl Oncol. 2017 Aug;10(4):641-649. doi: 10.1016/j.tranon.2017.04.012. Epub 2017 Jun 29.

Mangafodipir a Selective Cytoprotectant - with Special Reference to Oxaliplatin and Its Association to Chemotherapy-Induced Peripheral Neuropathy (CIPN).

Translational oncology

Jan Olof G Karlsson, Rolf Gg Andersson, Per Jynge

Affiliations

  1. Division of Drug Research/Pharmacology, Linköping University, Sweden. Electronic address: [email protected].
  2. Division of Drug Research/Pharmacology, Linköping University, Sweden.

PMID: 28668762 PMCID: PMC5496205 DOI: 10.1016/j.tranon.2017.04.012

Abstract

Oxaliplatin, in combination with 5-fluorouracil plus folinate (or capecitabine), has increased survival substantially in stage III colorectal cancer and prolonged life in stage IV patients, but its use is compromised because of severe toxicity. Chemotherapy-induced peripheral neuropathy (CIPN) is the most problematic dose-limiting toxicity of oxaliplatin. Oncologists included for years calcium and magnesium infusion as part of clinical practice for preventing CIPN. Results from a phase III prospective study published in 2014, however, overturned this practice. No other treatments have been clinically proven to prevent this toxicity. There is a body of evidence that CIPN is caused by cellular oxidative stress. Clinical and preclinical data suggest that the manganese chelate and superoxide dismutase mimetic mangafodipir (MnDPDP) is an efficacious inhibitor of CIPN and other conditions caused by cellular oxidative stress, without interfering negatively with the tumoricidal activity of chemotherapy. MnPLED, the metabolite of MnDPDP, attacks cellular oxidative stress at several critical levels. Firstly, MnPLED catalyzes dismutation of superoxide (O

Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

References

  1. Lancet Oncol. 2014 Oct;15(11):1245-53 - PubMed
  2. Transl Oncol. 2012 Feb;5(1):32-8 - PubMed
  3. Redox Biol. 2014 Jan 18;2:289-95 - PubMed
  4. Acc Chem Res. 2013 Feb 19;46(2):550-9 - PubMed
  5. J Natl Cancer Inst. 2006 Feb 15;98(4):236-44 - PubMed
  6. Br J Cancer. 2011 Jun 28;105(1):58-64 - PubMed
  7. Br J Clin Pharmacol. 2014 Nov;78(5):950-60 - PubMed
  8. Science. 1983 Jul 1;221(4605):75-7 - PubMed
  9. Acta Radiol. 1997 Jul;38(4 Pt 2):665-76 - PubMed
  10. J Clin Invest. 2014 Jan;124(1):262-72 - PubMed
  11. J Clin Oncol. 2007 Sep 1;25(25):4028-9 - PubMed
  12. J Clin Oncol. 2011 Feb 1;29(4):421-7 - PubMed
  13. J Clin Oncol. 2004 Jan 1;22(1):31-8 - PubMed
  14. Pain. 2012 Mar;153(3):704-9 - PubMed
  15. Biochem Biophys Res Commun. 1999 Jan 27;254(3):768-72 - PubMed
  16. Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4055-61 - PubMed
  17. Ann Intern Med. 1995 Mar 1;122(5):321-6 - PubMed
  18. Exp Neurol. 2011 Dec;232(2):154-61 - PubMed
  19. Curr Colorectal Cancer Rep. 2013;9:261-269 - PubMed
  20. Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4003-8 - PubMed
  21. Acta Oncol. 2009;48(4):633-5 - PubMed
  22. Biochim Biophys Acta. 1997 Mar 14;1331(1):1-40 - PubMed
  23. J Biol Chem. 1998 Sep 18;273(38):24521-8 - PubMed
  24. Transl Oncol. 2012 Aug;5(4):252-9 - PubMed
  25. J Clin Oncol. 2008 Mar 1;26(7):1188-9; author reply 1189-90 - PubMed
  26. J Clin Oncol. 2005 Dec 1;23(34):8671-8 - PubMed
  27. Curr Cancer Drug Targets. 2010 Nov;10(7):670-82 - PubMed
  28. J Pharmacol Exp Ther. 1994 Nov;271(2):609-14 - PubMed
  29. Neuroscience. 2012 Feb 17;203:194-206 - PubMed
  30. Am J Transl Res. 2016 Feb 15;8(2):799-810 - PubMed
  31. J Biol Chem. 1973 May 25;248(10):3582-92 - PubMed
  32. CA Cancer J Clin. 2013 Nov-Dec;63(6):419-37 - PubMed
  33. J Biol Chem. 1973 Jul 10;248(13):4793-6 - PubMed
  34. Biochem J. 2011 Mar 15;434(3):365-81 - PubMed
  35. Pain. 2013 Nov;154(11):2432-40 - PubMed
  36. Oncologist. 2008 Oct;13(10):1074-83 - PubMed
  37. Neuro Oncol. 2012 Sep;14 Suppl 4:iv45-54 - PubMed
  38. Ann Oncol. 2015 Nov;26(11):2280-6 - PubMed
  39. Cochrane Database Syst Rev. 2014 Mar 31;(3):CD005228 - PubMed
  40. J Biol Chem. 1968 Nov 10;243(21):5753-60 - PubMed
  41. Redox Rep. 2014 Nov;19(6):221-31 - PubMed
  42. J Biol Chem. 1969 Nov 25;244(22):6049-55 - PubMed
  43. Cell Calcium. 2014 Dec;56(6):437-45 - PubMed
  44. Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11853-8 - PubMed
  45. J Clin Oncol. 2004 Jan 1;22(1):23-30 - PubMed
  46. Crit Rev Toxicol. 2005 Jan;35(1):1-32 - PubMed
  47. Ann Oncol. 2007 Mar;18(3):581-92 - PubMed
  48. Cancer Res. 2005 Feb 1;65(3):948-56 - PubMed
  49. Am J Clin Nutr. 2002 Jan;75(1):112-8 - PubMed
  50. J Pharmacol Exp Ther. 2011 Apr;337(1):110-6 - PubMed
  51. Drug Discov Today. 2015 Apr;20(4):411-21 - PubMed
  52. J Clin Oncol. 1998 Jan;16(1):295-300 - PubMed
  53. J Natl Cancer Inst. 2006 Feb 15;98(4):223-5 - PubMed
  54. Eur J Pharmacol. 2010 Aug 25;640(1-3):124-8 - PubMed
  55. Toxicol Sci. 1998 Dec;46(2):342-51 - PubMed
  56. J Clin Oncol. 2000 Aug;18(16):2938-47 - PubMed
  57. J Exp Med. 2005 Apr 18;201(8):1257-68 - PubMed
  58. Int J Cancer. 2011 Feb 1;128(3):682-90 - PubMed
  59. N Engl J Med. 2004 Jun 3;350(23):2343-51 - PubMed
  60. Chem Res Toxicol. 1996 Jul-Aug;9(5):836-44 - PubMed
  61. Am J Physiol. 1996 Nov;271(5 Pt 1):C1424-37 - PubMed
  62. J Clin Oncol. 2014 Apr 1;32(10):997-1005 - PubMed
  63. Transl Oncol. 2012 Dec;5(6):492-502 - PubMed

Publication Types